SCHEMBL3754790

SCHEMBL3754790

Cc1c(-c2ccccc2)[c]ncc1N1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 4/20 0.43
NCF1 P14598 1/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.38
CASP1 P29466 1/20 0.38
CASP3 P42574 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751377 0.98 NPY5R (0.41) NPY5RNCF1ALDH1A1GAAKDM4E
SCHEMBL3759013 0.87 HTR7 (0.53) NCF1
SCHEMBL3769533 0.86 HTR6 (0.49) NCF1
SCHEMBL3754803 0.86 NCF1 (0.44) NCF1ALDH1A1GAAKDM4ENPC1
SCHEMBL3760229 0.77 KDM4E (0.43) NPY5RNCF1ALDH1A1GAAKDM4E
SCHEMBL3756163 0.75 KDM4E (0.41) NCF1ALDH1A1GAAKDM4EL3MBTL1
SCHEMBL3765086 0.74 TSHR (0.49) ALDH1A1GAANPC1RAB9AKMT2A
SCHEMBL3996914 0.74 SRD5A1 (0.38) NPC1RAB9A
SCHEMBL3757772 0.73 HSD17B10 (0.40) NCF1ALDH1A1GAAKDM4EL3MBTL1
SCHEMBL3759744 0.73 NPY5R (0.36) NPY5RALDH1A1GAAKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA NPY5R 4725/4885NCF1 3041/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.